title: Antibody-Antibiotic Conjugates: A Novel Therapeutic Platform against Bacterial Infections.
abstract: Antibodies are potent components of the immune repertoire and have been successfully exploited to treat bacterial infections. Recently an antibody-antibiotic conjugate (AAC) that combines key attributes of an antibody and antibiotic has been shown to be efficacious against Staphylococcus aureus infection. An AAC has three components: an antibiotic payload to kill bacteria, an antibody to target delivery of the payload to bacteria, and a linker attaching the payload to the antibody. With increasing understanding of the biology and pathophysiology of S. aureus, this article highlights how this knowledge has led to the design principles of an efficacious AAC, and discusses how the AAC platform could be translationally applied to treat other perilous infectious diseases.
authors.affiliation: Department of Late-Stage Oncology Biomarkers Development, Genentech Inc., 1 DNA Way, South San Francisco, CA 94080, USA. Electronic address: mariathasan.sanjeev@gene.com.
authors.forename: Sanjeev
authors.initials: S
authors.lastname: Mariathasan
authors.affiliation: Department of Infectious Diseases, Genentech Inc., 1 DNA Way, South San Francisco, CA 94080, USA. Electronic address: tan.man-wah@gene.com.
authors.forename: Man-Wah
authors.initials: MW
authors.lastname: Tan
mesh_terms: D000818:Animals; D000900:Anti-Bacterial Agents / Q000493:pharmacokinetics / Q000494:pharmacology / Q000627:therapeutic use*; D006801:Humans; D018796:Immunoconjugates / Q000493:pharmacokinetics / Q000494:pharmacology / Q000627:therapeutic use*; D013203:Staphylococcal Infections / Q000188:drug therapy* / Q000503:physiopathology; D013211:Staphylococcus aureus / Q000187:drug effects* / Q000502:physiology
chemical_list: D000900:Anti-Bacterial Agents; D018796:Immunoconjugates